Cargando…
Prognostic Value of a Three-DNA Methylation Biomarker in Patients with Soft Tissue Sarcoma
Soft tissue sarcomas (STS) are a highly aggressive and heterogeneous group of malignant mesenchymal tumors. The prognosis of patients with advanced or metastatic STS remains poor, and the main therapy of STS patients combines primary surgery, radiotherapy, and chemotherapy. Aberrant DNA methylation...
Autores principales: | Chen, Yuxiao, Zhu, Rui, Chen, Min, Guo, Wenna, Yang, Xin, Xu, Xin-Jian, Zhu, Liucun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245661/ https://www.ncbi.nlm.nih.gov/pubmed/32508922 http://dx.doi.org/10.1155/2020/8106212 |
Ejemplares similares
-
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
por: Guo, Wenna, et al.
Publicado: (2018) -
A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma
por: Guo, Wenna, et al.
Publicado: (2019) -
Identification and Validation of Ferroptosis-Related DNA Methylation Signature for Predicting the Prognosis and Guiding the Treatment in Cutaneous Melanoma
por: Guo, Wenna, et al.
Publicado: (2022) -
Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
por: Merry, Eve, et al.
Publicado: (2021) -
Prognostic Value of PLAGL1-Specific CpG Site Methylation in Soft-Tissue Sarcomas
por: Peille, Anne-Lise, et al.
Publicado: (2013)